1 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
2 Department of Health Research Methods, Evidence and Impact. McMaster University, Hamilton, Ontario, Canada.
Ann Am Thorac Soc. 2017 Dec;14(12):1818-1826. doi: 10.1513/AnnalsATS.201612-1042OC.
Clinicians' current practice patterns in the management of acute respiratory distress syndrome (ARDS) and refractory hypoxemia are not well described.
To describe mechanical ventilation strategies and treatment adjuncts for adults with ARDS, including refractory hypoxemia.
This was a prospective cohort study (March 2014-February 2015) of mechanically ventilated adults with moderate-to-severe ARDS requiring an Fi of 0.50 or greater in 24 intensive care units.
We enrolled 664 patients: 222 (33%) with moderate and 442 (67%) with severe ARDS. On Study Day 1, mean Vt was 7.5 (SD = 2.1) ml/kg predicted body weight (n = 625); 80% (n = 501) received Vt greater than 6 ml/kg. Mean positive end-expiratory pressure (PEEP) was 10.5 (3.7) cm HO (n = 653); 568 patients (87%) received PEEP less than 15 cm HO. Treatment adjuncts were common (n = 440, 66%): neuromuscular blockers (n = 276, 42%), pulmonary vasodilators (n = 118, 18%), prone positioning (n = 67, 10%), extracorporeal life support (n = 29, 4%), and high-frequency oscillatory ventilation (n = 29, 4%). Refractory hypoxemia, defined as Pa less than 60 mm Hg on Fi of 1.0, occurred in 138 (21%) patients. At onset of refractory hypoxemia, mean Vt was 7.1 (SD = 2.0) ml/kg (n = 124); 95 patients (77%) received Vt greater than 6 ml/kg. Mean PEEP was 12.1 (SD = 4.4) cm HO (n = 133); 99 patients (74%) received PEEP less than 15 cm HO. Among patients with refractory hypoxemia, 91% received treatment adjuncts (126/138), with increased use of neuromuscular blockers (n = 87, 63%), pulmonary vasodilators (n = 57, 41%), and prone positioning (n = 32, 23%).
Patients with moderate-to-severe ARDS receive treatment adjuncts frequently, especially with refractory hypoxemia. Paradoxically, therapies with less evidence supporting their use (e.g., pulmonary vasodilators) were over-used, whereas those with more evidence (e.g., prone positioning, neuromuscular blockade) were under-used. Patients received higher Vts and lower PEEP than would be suggested by the evidence.
临床医生目前在急性呼吸窘迫综合征(ARDS)和难治性低氧血症的管理中的实践模式尚未得到很好的描述。
描述成人 ARDS 患者,包括难治性低氧血症患者的机械通气策略和治疗辅助手段。
这是一项前瞻性队列研究(2014 年 3 月至 2015 年 2 月),纳入了在 24 个重症监护病房中需要吸入氧分数(FiO2)大于等于 0.50 的中重度 ARDS 机械通气成人患者。
我们共纳入了 664 例患者:222 例(33%)为中度 ARDS,442 例(67%)为重度 ARDS。在研究第 1 天,平均潮气量(Vt)为 7.5(标准差[SD] 2.1)ml/kg 预测体重(n=625);80%(n=501)接受的 Vt 大于 6 ml/kg。平均呼气末正压(PEEP)为 10.5(3.7)cm H2O(n=653);568 例患者(87%)接受的 PEEP 小于 15 cm H2O。治疗辅助手段很常见(n=440,66%):神经肌肉阻滞剂(n=276,42%)、肺血管扩张剂(n=118,18%)、俯卧位通气(n=67,10%)、体外生命支持(n=29,4%)和高频振荡通气(n=29,4%)。难治性低氧血症定义为 FiO2 为 1.0 时 PaO2 小于 60mmHg,发生在 138 例(21%)患者中。在难治性低氧血症出现时,平均 Vt 为 7.1(SD 2.0)ml/kg(n=124);95 例患者(77%)接受的 Vt 大于 6 ml/kg。平均 PEEP 为 12.1(SD 4.4)cm H2O(n=133);99 例患者(74%)接受的 PEEP 小于 15 cm H2O。在难治性低氧血症患者中,91%(126/138)接受了治疗辅助手段,其中神经肌肉阻滞剂(n=87,63%)、肺血管扩张剂(n=57,41%)和俯卧位通气(n=32,23%)的使用率更高。
中重度 ARDS 患者经常接受治疗辅助手段,尤其是在出现难治性低氧血症时。矛盾的是,使用证据支持较少的疗法(如肺血管扩张剂)过度使用,而使用证据更多的疗法(如俯卧位通气、神经肌肉阻滞剂)则使用不足。患者接受的 Vt 更高,PEEP 更低,这与证据不符。